ANN ARBOR, Mich., May 23, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following webcasted investor events during the month of May, which can be found on our investor relations website. Jefferies Global Healthcare Conference in New York on June 5, 2024, at 4:30 p.m. ET. Goldman Sachs Healthcare Conference in Miami Beach on June 12, 2024, at 8:40 a.m. ET. Live webcasts can be accessed on the investor and media section of the Esperion website. ...

ANN ARBOR, Mich., May 23, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following webcasted investor events during the month of May, which can be found on our investor relations website. Jefferies Global Healthcare Conference in New York on June 5, 2024, at 4:30 p.m. ET. Goldman Sachs Healthcare Conference in Miami Beach on June 12, 2024, at 8:40 a.m. ET. Live webcasts can be accessed on the investor and media section of the Esperion website. ...

Core Insights - The European Commission has approved label updates for NILEMDO (bempedoic acid) and NUSTENDI (bempedoic acid/ezetimibe fixed-dose combination) as treatments to reduce cardiovascular risk by lowering LDL-C levels, making bempedoic acid the first and only LDL-C lowering treatment indicated for both primary and secondary prevention of cardiovascular events [1][2][3] Group 1: Approval and Indications - The approval is based on positive results from the CLEAR Outcomes trial, which involved 13,970 patients across 1,250 sites in 32 countries, including 485 sites in Europe [6][17] - Bempedoic acid and its fixed-dose combination are indicated for adults with established or at high risk for atherosclerotic cardiovascular disease to lower LDL-C levels and reduce cardiovascular risk [2][15] Group 2: Market Need and Impact - Approximately one in seven people in Europe have high LDL-C levels, with cardiovascular disease being the leading cause of death, resulting in over 10,000 deaths daily [3] - Up to 80% of patients do not achieve guideline-recommended LDL-C goals despite treatment with statins, indicating a significant unmet medical need [3][4] Group 3: Efficacy of Treatments - Bempedoic acid can provide an additional cholesterol lowering of up to 28% on top of statin therapy compared to placebo [4] - The bempedoic acid/ezetimibe fixed-dose combination reduced LDL-C by 38% compared to placebo in high-risk patients already on maximum-tolerated statin therapy [4][15] Group 4: Statements from Company Executives - Company representatives expressed confidence that the new indication will help healthcare professionals better meet treatment needs and reassure patients about their cardiovascular risk management [5][6]

ANN ARBOR, Mich., May 20, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) and Otsuka Pharmaceutical Co., Ltd (Otsuka) announced today that the primary endpoint was achieved in the Phase 3 trial in Japan for bempedoic acid as a potential treatment for patients with hypercholesterolemia. The trial demonstrated statistically significant outcomes on the primary endpoint for bempedoic acid and highlighted its potential future value to patients in Japan. INDICATION Bempedoic acid, created by Esperion Therapeutics ...

ANN ARBOR, Mich., May 20, 2024 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) and Otsuka Pharmaceutical Co., Ltd (Otsuka) announced today that the primary endpoint was achieved in the Phase 3 trial in Japan for bempedoic acid as a potential treatment for patients with hypercholesterolemia. The trial demonstrated statistically significant outcomes on the primary endpoint for bempedoic acid and highlighted its potential future value to patients in Japan. Bempedoic acid, created by Esperion Therapeutics, Inc. (Es ...

ANN ARBOR, Mich., May 10, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that on May 8, 2024, the Company granted 16 new employees 62,300 restricted stock units (RSUs) under Esperion's 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement material to such ind ...

Esperion Therapeutics, Inc. (ESPR) reported earnings of 34 cents per share in the first quarter of 2024, against the Zacks Consensus Estimate of a loss of 8 cents. The company incurred a loss of 79 cents per share in the year-ago quarter.Esperion generated revenues of $137.7 million, up nearly 467% year over year. The upside was driven by the receipt of a milestone payment and increased demand for the company’s drugs across all regions. Per management, this is the highest level of revenues generated by the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35986 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or ...

Esperion Therapeutics (ESPR) came out with quarterly earnings of $0.34 per share, beating the Zacks Consensus Estimate of a loss of $0.08 per share. This compares to loss of $0.79 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 525%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.53 per share when it actually produced a loss of $0.50, delivering a surprise of 5.66%.Over the last four ...

– Q1 Retail Prescription Equivalents Grew 43% Y/Y and 6% Q/Q, Increased Momentum from Label Expansions Expected Throughout 2024 – – Received U.S. FDA Approval of Broad New Label Expansions for NEXLETOL (bempedoic acid) Tablet and NEXLIZET (bempedoic acid and ezetimibe) Tablet, Becoming the First LDL-C Lowering Non- Statins to Prevent Heart Attacks and Reduce Cardiovascular Risk in Primary and Secondary Prevention Patients – ® ® Exhibit 99.1 Esperion Reports First Quarter 2024 Financial Results – Q1 Total Re ...